评估瑞士65岁及以上成人PCV15疫苗接种项目的健康与经济结局
该研究采用静态马尔可夫状态转换模型,评估瑞士65岁及以上成人接种PCV13或PCV15疫苗项目的健康与经济结局,时间跨度35年,贴现率3.0%,成本按2023年瑞士法郎计。结果显示,在60%覆盖率假设下,PCV15策略较不接种可预防大量肺炎球菌疾病病例和死亡,且ICER为每获得一个QALY花费20,479瑞士法郎,具有成本效果。
要点
- PCV15策略较不接种可预防1,078例侵袭性肺炎球菌疾病、21,155例非菌血症性肺炎球菌肺炎和493例死亡。
- PCV15策略的ICER为每获得一个QALY花费20,479瑞士法郎。
- 敏感性分析中PCV15策略的ICER均低于每获得一个QALY花费30,000瑞士法郎。
核心结论
- 在65岁及以上成人中使用PCV15可预防大量肺炎球菌疾病病例和死亡,并在多种输入和情景下保持成本效果。
研究设计与样本
- 研究采用静态马尔可夫状态转换模型,目标人群为瑞士所有65岁及以上成人,视角为瑞士医疗保健支付方,时间跨度为35年,贴现率3.0%,成本按2023年瑞士法郎计,数据来源于已发表文献和公开数据库或报告。
主要发现
- 在假设60%覆盖率下,与不接种策略相比,PCV15策略预防1,078例侵袭性肺炎球菌疾病、21,155例非菌血症性肺炎球菌肺炎和493例死亡。
- 总QALY分别为10,364,620(PCV15)、10,364,070(PCV13)和10,362,490(不接种)。
- 总成本分别为741,949,814瑞士法郎(PCV15)、756,051,954瑞士法郎(PCV13)和698,329,579瑞士法郎(不接种)。
- PCV13策略被PCV15策略强支配;PCV15策略相较不接种的ICER为每获得一个QALY花费20,479瑞士法郎。
- 在血清型3疫苗效力降低(IPD从75%降至39.3%,NBPP从45%降至23.6%)和NBPP发病率增加(从1,346/100,000增至1,636/100,000)的情景分析中,ICER分别为每获得一个QALY花费29,432瑞士法郎和13,700瑞士法郎。
关键数值与推荐
- 确定性敏感性和概率敏感性分析显示定性结果稳健,PCV15策略(对比不接种)的ICER估计值均低于每获得一个QALY花费30,000瑞士法郎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the health and economic outcomes of a PCV13 or PCV15 age-based (65 years-and-above) vaccination program in Switzerland. INTERVENTIONS: The three vaccination strategies examined were:Target population: All adults aged 65 years-and-above. Perspective(s): Switzerland health care payer. TIME HORIZON: 35 years. Discount rate: 3.0%. Costing year: 2023 Swiss Francs (CHF). STUDY DESIGN: A static Markov state-transition model. DATA SOURCES: Published literature and publicly available databases or reports. OUTCOME MEASURES: Pneumococcal diseases (PD) i.e., invasive pneumococcal diseases (IPD) and non-bacteremic pneumococcal pneumonia (NBPP); total quality-adjusted life-years (QALYs), total costs and incremental cost-effectiveness ratios (CHF/QALY gained). RESULTS: Using an assumed coverage of 60%, the PCV15 strategy prevented a substantially higher number of cases/deaths than the PCV13 strategy when compared to the No vaccination strategy (1,078 IPD; 21,155 NBPP; 493 deaths). The overall total QALYs were 10,364,620 (PCV15), 10,364,070 (PCV13), and 10,362,490 (no vaccination). The associated overall total costs were CHF 741,949,814 (PCV15), CHF 756,051,954 (PCV13) and CHF 698,329,579 (no vaccination). Thus, the PCV13 strategy was strongly dominated by the PCV15 strategy. The ICER of the PCV15 strategy (vs. no vaccination) was CHF 20,479/QALY gained. In two scenario analyses where the vaccine effectiveness for serotype 3 were reduced (75% to 39.3% for IPD; 45% to 23.6% for NBPP) and NBPP incidence was increased (from 1,346 to 1,636/100,000), the resulting ICERs were CHF 29,432 and CHF 13,700/QALY gained, respectively. The deterministic and probabilistic sensitivity analyses demonstrated the robustness of the qualitative results-the estimated ICERs for the PCV15 strategy (vs. No vaccination) were all below CHF 30,000/QALYs gained. CONCLUSIONS: These results demonstrate that using PCV15 among adults aged 65 years-and-above can prevent a substantial number of PD cases and deaths while remaining cost-effective over a range of inputs and scenarios.
引用
- Owusu-Edusei K, Favre-Bulle A, Tsoumani E, et al. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland. Vaccine. 2024. PMID: 38609806. doi:10.1016/j.vaccine.2024.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。